Literature DB >> 6336308

Patient with 13 chromosome deletion: evidence that the retinoblastoma gene is a recessive cancer gene.

W F Benedict, A L Murphree, A Banerjee, C A Spina, M C Sparkes, R S Sparkes.   

Abstract

Although a constitutional chromosomal deletion including 13q14 has been found to date in all retinoblastoma patients whose esterase D activity is 50 percent of normal, one female patient has been found who has 50 percent esterase D activity in all normal cells examined but no deletion of 13q14 at the 550-band level. Therefore, she has the smallest constitutional chromosomal deletion within 13q14 that is associated with susceptibility to retinoblastoma. Two stem lines were identified in a retinoblastoma from this patient, and each one had a missing 13 chromosome. No detectable esterase D activity was found in the tumor, indicating that the normal nondeleted 13 chromosome was lost in both stem lines. Thus the data from this patient not only show that there is a total loss of genetic information at the location of the retinoblastoma gene within the tumor, but also imply that recessive genes may play an important role in the development of certain human tumors including retinoblastoma.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6336308     DOI: 10.1126/science.6336308

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  70 in total

Review 1.  Molecular biology and respiratory disease. 4. Cancer genes.

Authors:  K Sikora; G Ong
Journal:  Thorax       Date:  1990-05       Impact factor: 9.139

Review 2.  A continuum model for tumour suppression.

Authors:  Alice H Berger; Alfred G Knudson; Pier Paolo Pandolfi
Journal:  Nature       Date:  2011-08-10       Impact factor: 49.962

3.  Deletion of RB exons 24 and 25 causes low-penetrance retinoblastoma.

Authors:  R Bremner; D C Du; M J Connolly-Wilson; P Bridge; K F Ahmad; H Mostachfi; D Rushlow; J M Dunn; B L Gallie
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

4.  Ophthalmology-important advances in clinical medicine: ophthalmic genetics: a new synthesis.

Authors:  J B Bateman
Journal:  West J Med       Date:  1984-02

5.  Ophthalmology: recessive human cancer genes.

Authors:  A L Murphree
Journal:  West J Med       Date:  1986-04

6.  Targeting tumor suppressor networks for cancer therapeutics.

Authors:  Xuning Emily Guo; Bryan Ngo; Aram Sandaldjian Modrek; Wen-Hwa Lee
Journal:  Curr Drug Targets       Date:  2014-01       Impact factor: 3.465

7.  Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma.

Authors:  V Greger; E Passarge; W Höpping; E Messmer; B Horsthemke
Journal:  Hum Genet       Date:  1989-09       Impact factor: 4.132

8.  Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy.

Authors:  Tadeusz Majewski; Sangkyou Lee; Joon Jeong; Dong-Sup Yoon; Andrzej Kram; Mi-Sook Kim; Tomasz Tuziak; Jolanta Bondaruk; Sooyong Lee; Weon-Seo Park; Kuang S Tang; Woonbok Chung; Lanlan Shen; Saira S Ahmed; Dennis A Johnston; H Barton Grossman; Colin P Dinney; Jain-Hua Zhou; R Alan Harris; Carrie Snyder; Slawomir Filipek; Steven A Narod; Patrice Watson; Henry T Lynch; Adi Gazdar; Menashe Bar-Eli; Xifeng F Wu; David J McConkey; Keith Baggerly; Jean-Pierre Issa; William F Benedict; Steven E Scherer; Bogdan Czerniak
Journal:  Lab Invest       Date:  2008-05-05       Impact factor: 5.662

9.  Measurements of the frequency of human erythrocytes with gene expression loss phenotypes at the glycophorin A locus.

Authors:  R G Langlois; W L Bigbee; R H Jensen
Journal:  Hum Genet       Date:  1986-12       Impact factor: 4.132

10.  Selection of human cells having two different types of mutations in individual cells (genetic/artificial mutants). Application to the diagnosis of the heterozygous state for a type of adenine phosphoribosyltransferase deficiency.

Authors:  N Kamatani; S Kuroshima; C Terai; K Kawai; K Mikanagi; K Nishioka
Journal:  Hum Genet       Date:  1987-06       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.